After Weiya was fined 1.3 billion, it did not affect her to continue to make a lot of money in another capacity, and with the successful listing of the "first share of collagen" Juzi Bio, Weiya's husband Dong Haifeng earned 100 million Hong Kong dollars.
On Friday, Juzi Bio, known as the "Huawei of the beauty industry", went public, once rose more than 25% during the session, and closed up 9.88% as of the close, and today, Juzi Biotech rose again by 17.98% to close at HK $31.5 per share, with a total market value of HK $31.236 billion.
Weiya's husband Dong Haifeng is the ultimate beneficiary of Juzi Bio's investor Qianyi Holdings Limited (hereinafter referred to as "Qianyi"), according to the prospectus, he holds 0.84% of the equity of Juzi Biotech after the global offering, and based on the rough calculation of Juzi Bio's closing price today, the market value of Juzi Bio's shares held by Weiya and his wife is about HK $262 million, compared with the cost of HK $167 million when they joined the shares in January 2022, and a net profit of nearly HK $100 million in just ten months.
"Huawei in the beauty industry" was listed, and Weiya's husband made a floating profit of 100 million
For Juzi Bio, Wei Ya is a noble person, at the beginning of the business, it spent a long period of tepid time, until Wei Ya's strong recommendation in the live broadcast room, Juzi Bio's products became famous and occupied the e-commerce sales list all year round.
Juzi Bio's brand "Kefumei" has also appeared in Weiya's live broadcast room many times, the two sides have cooperated in many live broadcasts, in 2021, Weiya also stood for Juzi Bio at the Haikou Consumer Expo, and in 2021, when the "Double 11" opened the pre-sale in advance, Fumei became the top 5 of Weiya's live broadcast room sales, reaching more than 50 million yuan, on the day of "Double Eleven", relying on Weiya's strong promotion in the live broadcast room, the cumulative turnover of Juzi Bio's main brand Kefumei exceeded 100 million yuan in 13 minutes.
After becoming a resident brand of Weiya live broadcast room, Juzi Biotech quickly accumulated industry prestige, the prospectus shows that the performance of Juzi Bio in the past three years has continued to grow, in 2019, Juzi Bio achieved revenue of 957 million yuan, in 2020 has broken the 1 billion yuan mark to 1.191 billion yuan, in 2021 further increased to 1.552 billion yuan, from January to May 31 this year, the company has also achieved revenue of 723 million yuan, an increase of 202 million yuan over the same period in 2021.
From the perspective of net profit, from 2019 to the first five months of 2022, the net profit of Juzi Biotech was 575 million yuan, 826 million yuan, 828 million yuan and 314 million yuan respectively, and during the same period, the adjusted net profit was 575 million yuan, 827 million yuan, 851 million yuan and 336 million yuan respectively.
From the perspective of specific business, the Fumei and Cleargold strongly recommended by Weiya have supported most of the performance of Juzi Bio. According to the prospectus, from 2019 to the first five months of 2022, the combined revenue of the above two brands was 771 million yuan, 981 million yuan, 1.424 billion yuan and 667 million yuan respectively.
More exaggerated, in addition to the continuous growth of revenue and net profit, Juzi Bio's gross profit margin is even more amazing, the prospectus shows that from 2019 to the first five months of 2022, Juzi Bio's gross profit margin is 83.3%, 84.6%, 87.2%, 85.0%, taking 2021 as an example, the flush iFinD shows that among the 4981 A-share companies, there are only 55 listed companies with higher gross profit margins than Juzi Biotech in 2021, that is, In 2021, the gross profit margin of professional skin care products of Juzi Biotech exceeded 98% of A-share companies.
For Weiya, Juzi Biotech is the financial owner, and it is also before the listing in January 2022, when Juzi Biotech obtained the Pre IPO round of financing, Weiya's Qianxun Culture suddenly entered the shares, according to the prospectus, a company named "Qianyi Holdings Limited" (hereinafter referred to as "Qianyi") was included in the investor list, It participated in the A-1 round of preferred stock and A-2 preferred stock financing of Juzi Biotech for a total consideration of 168 million yuan, holding 0.86% of the equity of Juzi Biotech before the global offering, followed by 0.84% of the equity after the global offering.
Qianyi is a company incorporated in the British Virgin Islands on October 11, 2021, controlled by Shanghai Qianyi Enterprise Management Partnership (Limited Partnership) (hereinafter referred to as "Shanghai Qianyi"), and Tianyan inspection shows that the ultimate beneficiary of Shanghai Qianyi is Weiya's husband Dong Haifeng.
Another participating company is about to go public
It is worth mentioning that in addition to Juzi Bio, Weiya's husband Dong Haifeng also appeared in the shareholder list of Guangdong Delmar Technology Co., Ltd. (hereinafter referred to as "Delmar"), a GEM IPO company, and invested in Delmar with 150 million yuan, and the timing was also very clever, because this is Delmar's last round of financing before the IPO.
Specifically, in November 2020, Dong Haifeng increased capital to Delmar by 150 million yuan to obtain 2.84% of the company's equity, according to Delmar's prospectus (2022-09-28 version), if the company is successfully listed, the proportion of Delmar shares held by Dong Haifeng after this issuance is 2.27%.
Delmar is also a product that Weiya has strongly recommended when she brought goods live, public information shows that Delmar is mainly engaged in vacuum cleaners, water purifiers, massagers and other innovative home appliances, and the company's brands include "Delmar", "Philips", "Weixin" and so on.
Compared with Juzi Bio, Delmar's revenue has increased in the past three years, but the growth rate of net profit attributable to the parent has slowed down. Previously, according to its prospectus, from 2019 to 2021, Delmar's revenue was 1.517 billion yuan, 2.228 billion yuan and 3.038 billion yuan respectively, a year-on-year increase of 56.91%, 46.89% and 53.27% respectively; The net profit attributable to the parent was 111 million, 173 million and 170 million yuan respectively, a year-on-year increase of 173.80%, 56.55% and -1.85% respectively.
Based on the latest transfer/capital increase price of 50 yuan per share in the pre-IPO round, Delmar's pre-listing valuation has reached 5.275 billion yuan.
According to Tianyancha data, at present, Weiya is associated with a total of 16 companies and serves as the legal representative in 10 companies, while there are 25 enterprises associated with Dong Haifeng, and there are 20 companies that serve as legal representatives, involving foreign trade, retail, consulting, enterprise management, e-commerce, etc.
This year's Double 11, Wei Ya's name has disappeared from the live broadcast rivers and lakes, but in the capital market, Wei Ya brushed a wave of existence. (Blackpool Finance)